Stress hormones can reawaken sleeping tumor cells, raising risk of cancer recurrence

December 02, 2020

Stress hormones and immune cells called neutrophils may contribute to the recurrence of tumors years after treatment by awakening dormant cancer cells, suggests a study of mice and data from 80 patients with lung cancer. The experiments help answer the enduring question of why cancers can return long after seemingly being cured with chemotherapy or surgery; the results also hint that targeting stress hormones with approved drugs known as beta-blockers could potentially help prevent tumors from returning. The recurrence of tumors is one of the biggest causes of deaths in cancer patients, but it's unclear exactly what biological mechanisms prompt tumors to recur. However, studies have suggested that recurrence unfolds as dormant tumor cells, which initially spread during the early stages of cancer, become active once more. Michela Perego and colleagues discovered that stress hormones such as norepinephrine reactivated dormant lung and ovarian cancer cells in mice. Specifically, the scientists found that exposing the mice to stressful situations elevated levels of stress hormones, which caused neutrophils to release S100A8/A9 proteins and fatty molecules that in turn prompted tumor cells to reawaken from dormancy. However, tumor cells remained dormant in stressed-out mice that received an experimental beta-blocker. The team also studied serum samples from 80 patients who had their lung cancers surgically removed and saw that patients who harbored higher concentrations of S100A8/A9 were more likely to have experienced recurrence 33 months after surgery. Perego et al. say that beta blockers or compounds that target S100A8/A9 proteins should be evaluated as potential therapies to disrupt the reactivation process, but stress the need for more sophisticated models of tumor cell dormancy.

American Association for the Advancement of Science

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to